1
|
Yin H, Wang C, Shuai Y, Xie Z, Liu J. Pig-Derived Probiotic Bacillus tequilensis YB-2 Alleviates Intestinal Inflammation and Intestinal Barrier Damage in Colitis Mice by Suppressing the TLR4/NF-κB Signaling Pathway. Animals (Basel) 2024; 14:1989. [PMID: 38998101 PMCID: PMC11240761 DOI: 10.3390/ani14131989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2024] [Revised: 06/20/2024] [Accepted: 07/03/2024] [Indexed: 07/14/2024] Open
Abstract
The search for new probiotics has been regarded as an important approach to improving intestinal health in animals. Bacillus has many advantages, such as strong resistance to harmful external factors, wide distribution, and easy colonization of the intestine. Hence, this study aims to screen for a probiotic Bacillus strain that improves animal intestinal health and to elucidate its probiotic mechanism so as to provide probiotic resources for the development of feed-using probiotic formulations. In this research, a strain of Bacillus was isolated from adult pig feces and named B. tequilensis YB-2. In vitro probiotic experiments showed that B. tequilensis YB-2 had strong acid and bile salt resistance, indicating that this strain can customize in the intestine. To further explore the effect of B. tequilensis YB-2 upon animal intestinal health, DSS-induced murine colitis models were established, and the body weight, colonic morphology, inflammatory cytokines level, and intestinal-barrier- and TLR4/NF-κB-pathway-related protein were determined. The results showed that mice receiving drinking water with 3% DSS were found to develop colitis symptoms, including body weight loss and increased disease activity index (DAI); colon length and microvilli shedding were shortened; tight junctions were disrupted; goblet cells decreased; anti-inflammatory cytokines were inhibited; and pro-inflammatory cytokines and the TLR4/NF-κB signaling pathway were activated. Notably, orally received B. tequilensis YB-2 alleviated symptoms of DSS-induced colitis in mice. The above results indicated that B. tequilensis YB-2 was capable of improving colitis in mice by weakening inflammation and intestinal barrier damage, and its mechanism may involve the TLR4/NF-κB pathway. Overall, this research suggests that B. tequilensis YB-2 has the potential to serve as an animal feed additive to prevent intestinal inflammation.
Collapse
Affiliation(s)
- Heng Yin
- School of Life Science and Engineering, Southwest University of Science and Technology, Mianyang 621010, China
| | - Chengbi Wang
- School of Life Science and Engineering, Southwest University of Science and Technology, Mianyang 621010, China
| | - Yi Shuai
- School of Life Science and Engineering, Southwest University of Science and Technology, Mianyang 621010, China
| | - Zhuoya Xie
- School of Life Science and Engineering, Southwest University of Science and Technology, Mianyang 621010, China
| | - Jingbo Liu
- School of Life Science and Engineering, Southwest University of Science and Technology, Mianyang 621010, China
| |
Collapse
|
2
|
Zeng P, Zhang CZ, Fan ZX, Yang CJ, Cai WY, Huang YF, Xiang ZJ, Wu JY, Zhang J, Yang J. Effect of probiotics on children with autism spectrum disorders: a meta-analysis. Ital J Pediatr 2024; 50:120. [PMID: 38902804 PMCID: PMC11191217 DOI: 10.1186/s13052-024-01692-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Accepted: 06/10/2024] [Indexed: 06/22/2024] Open
Abstract
BACKGROUND Researches have found that alteration of intestinal flora may be closely related to the development of autism spectrum disorder (ASD). However, whether probiotics supplementation has a protective effect on ASD remains controversial. This meta-analysis aimed to analyze the outcome of probiotics in the treatment of ASD children. METHODS The Pubmed, Cochrane Library, Web of Science and Embase were searched until Sep 2022. Randomized controlled trials (RCTs) relevant to the probiotics and placebo treatment on ASD children were screened. Quality assessment of the included RCTs was evaluated by the Cochrane collaboration's tool. The primary outcomes were ASD assessment scales, including ABC (aberrant behavior checklist) and CBCL (child behavior checklist) for evaluating the behavior improvement, SRS (social responsiveness scale) for social assessment, DQ (developmental quotient) for physical and mental development and CGI-I (clinical global impression improvement) for overall improvement. The secondary outcome was total 6-GSI (gastrointestinal severity index). RESULTS In total, 6 RCTs from 6 studies with 302 children were included in the systemic review. Total 6-GSI (MD=-0.59, 95%CI [-1.02,-0.17], P < 0.05) decreased significantly after oral administration of probiotics. Whereas, there was no statistical difference in ABC, CBCL, SRS, DQ and CGI-I between probiotics and placebo groups in ASD children. CONCLUSION Probiotics treatment could improve gastrointestinal symptoms, but there was no significant improvement in ASD.
Collapse
Affiliation(s)
- Ping Zeng
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China
| | - Cheng-Zhi Zhang
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China
| | - Zhi-Xing Fan
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China
| | - Chao-Jun Yang
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China
| | - Wan-Yin Cai
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China
| | - Yi-Fan Huang
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China
| | - Zu-Jin Xiang
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China
| | - Jing-Yi Wu
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China
| | - Jing Zhang
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China.
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China.
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China.
| | - Jian Yang
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, 443003, China.
- Institute of Cardiovascular Diseases, Three Gorges University, Yichang, China.
- Hubei Key Laboratory of Ischemic Cardiovascular Disease and HuBei Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China.
| |
Collapse
|
3
|
da Silva P, Rohloff N, Catoia MRR, Kaufmann C, Tesser GLS, Weber SH, Campos FP, Silva LFCE, Ferreira AHDN, Nunes RV, Costa LB. Alternative to antimicrobial growth promoters in the diets of broilers challenged with subclinical necrotic enteritis. Poult Sci 2024; 103:103986. [PMID: 39003795 DOI: 10.1016/j.psj.2024.103986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2024] [Revised: 06/04/2024] [Accepted: 06/12/2024] [Indexed: 07/16/2024] Open
Abstract
Necrotic enteritis (NE) is a disease of worldwide distribution, which affects young broilers and causes economic losses on a scale of 6 billion dollars per year. For decades, NE was controlled in poultry flocks by dietary administration of low doses of antimicrobial growth promoters (AGPs). However, an increase in NE incidence was noted after the AGP ban. This study aimed to compare the effect of an antibiotic (Enramycin) diet to a combination of sodium butyrate, hydrolyzed yeast, and zinc proteinate (ViligenTM) on broiler diets regarding performance, blood parameters, intestinal permeability, morphology and lesions, and carcass yield of broilers challenged with Eimeria spp. and Clostridium perfringens to simulate subclinical necrotic enteritis. A total of 1,150 one-day-old male broiler chickens with an initial average weight of 43.9 ± 0.65 g were allocated to 50 experimental pens. Animals were divided into 5 groups: Negative control (NC) without additives; Positive control (PC) with 0.12 g/ton of Enramycin (8%); V500, V1000, and V1500 with the addition of 500, 1.000, and 1.500 g/ton of Viligen, respectively. All animals were challenged by Eimeria spp. at 7 d of age and by C. perfringens at 17, 18, and 19 d for induction of subclinical NE. The broilers fed with all concentrations of Viligen showed similar performance, blood parameters, intestinal permeability, and carcass yield compared to PC broilers. However, NC broilers showed higher FCR compared to PC broilers from 1 to 33 d (1.42 vs. 1.39) (P = 0.048) and from 1 to 42 d (1.51 vs. 1.49) (P < 0.001). V1500 broilers had fewer intestinal lesions at 28 d when compared to the PC treatment (P < 0.05) and showed that higher Viligen inclusion resulted in lower intestinal damage. At 21 d, the V500 group showed higher intestinal morphology characteristics (VH:VD 4.9 vs. 3.5) compared to the PC treatment (P < 0.001). Thus, in this study, the dietary addition of Viligen to broilers challenged by an experimental model of subclinical NE resulted in lower intestinal damage and similar performance to that obtained by the addition of Enramycin.
Collapse
Affiliation(s)
- Paola da Silva
- Pontifícia Universidade Católica do Paraná - Graduate Program of Animal Science, School of Medicine and Life Science - Curitiba, Paraná, Brazil
| | - Nilton Rohloff
- Universidade Estadual do Oeste do Paraná - Graduate Program in Animal Science - Marechal Candido Rondon, Paraná, Brazil
| | - Mariana R R Catoia
- Pontifícia Universidade Católica do Paraná - Graduate Program of Animal Science, School of Medicine and Life Science - Curitiba, Paraná, Brazil
| | - Cristine Kaufmann
- Universidade Estadual do Oeste do Paraná - Graduate Program in Animal Science - Marechal Candido Rondon, Paraná, Brazil
| | - Guilherme L S Tesser
- Universidade Estadual do Oeste do Paraná - Graduate Program in Animal Science - Marechal Candido Rondon, Paraná, Brazil
| | - Saulo H Weber
- Pontifícia Universidade Católica do Paraná - Graduate Program of Animal Science, School of Medicine and Life Science - Curitiba, Paraná, Brazil
| | - Felipe P Campos
- Universidade Estadual do Oeste do Paraná - Graduate Program in Animal Science - Marechal Candido Rondon, Paraná, Brazil
| | | | | | - Ricardo V Nunes
- Universidade Estadual do Oeste do Paraná - Graduate Program in Animal Science - Marechal Candido Rondon, Paraná, Brazil
| | - Leandro B Costa
- Pontifícia Universidade Católica do Paraná - Graduate Program of Animal Science, School of Medicine and Life Science - Curitiba, Paraná, Brazil.
| |
Collapse
|
4
|
Obianwuna UE, Agbai Kalu N, Wang J, Zhang H, Qi G, Qiu K, Wu S. Recent Trends on Mitigative Effect of Probiotics on Oxidative-Stress-Induced Gut Dysfunction in Broilers under Necrotic Enteritis Challenge: A Review. Antioxidants (Basel) 2023; 12:antiox12040911. [PMID: 37107286 PMCID: PMC10136232 DOI: 10.3390/antiox12040911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2023] [Revised: 02/18/2023] [Accepted: 03/02/2023] [Indexed: 04/29/2023] Open
Abstract
Gut health includes normal intestinal physiology, complete intestinal epithelial barrier, efficient immune response, sustained inflammatory balance, healthy microbiota, high nutrient absorption efficiency, nutrient metabolism, and energy balance. One of the diseases that causes severe economic losses to farmers is necrotic enteritis, which occurs primarily in the gut and is associated with high mortality rate. Necrotic enteritis (NE) primarily damages the intestinal mucosa, thereby inducing intestinal inflammation and high immune response which diverts nutrients and energy needed for growth to response mediated effects. In the era of antibiotic ban, dietary interventions like microbial therapy (probiotics) to reduce inflammation, paracellular permeability, and promote gut homeostasis may be the best way to reduce broiler production losses. The current review highlights the severity effects of NE; intestinal inflammation, gut lesions, alteration of gut microbiota balance, cell apoptosis, reduced growth performance, and death. These negative effects are consequences of; disrupted intestinal barrier function and villi development, altered expression of tight junction proteins and protein structure, increased translocation of endotoxins and excessive stimulation of proinflammatory cytokines. We further explored the mechanisms by which probiotics mitigate NE challenge and restore the gut integrity of birds under disease stress; synthesis of metabolites and bacteriocins, competitive exclusion of pathogens, upregulation of tight junction proteins and adhesion molecules, increased secretion of intestinal secretory immunoglobulins and enzymes, reduction in pro-inflammatory cytokines and immune response and the increased production of anti-inflammatory cytokines and immune boost via the modulation of the TLR/NF-ĸ pathway. Furthermore, increased beneficial microbes in the gut microbiome improve nutrient utilization, host immunity, and energy metabolism. Probiotics along with biosecurity measures could mitigate the adverse effects of NE in broiler production.
Collapse
Affiliation(s)
- Uchechukwu Edna Obianwuna
- National Engineering Research Center of Biological Feed, Institute of Feed Research, Chinese Academy of Agricultural Sciences, Beijing 100081, China
| | - Nenna Agbai Kalu
- Department of Animal Science, Ahmadu Bello University, Zaria 810211, Nigeria
| | - Jing Wang
- National Engineering Research Center of Biological Feed, Institute of Feed Research, Chinese Academy of Agricultural Sciences, Beijing 100081, China
| | - Haijun Zhang
- National Engineering Research Center of Biological Feed, Institute of Feed Research, Chinese Academy of Agricultural Sciences, Beijing 100081, China
| | - Guanghai Qi
- National Engineering Research Center of Biological Feed, Institute of Feed Research, Chinese Academy of Agricultural Sciences, Beijing 100081, China
| | - Kai Qiu
- National Engineering Research Center of Biological Feed, Institute of Feed Research, Chinese Academy of Agricultural Sciences, Beijing 100081, China
| | - Shugeng Wu
- National Engineering Research Center of Biological Feed, Institute of Feed Research, Chinese Academy of Agricultural Sciences, Beijing 100081, China
| |
Collapse
|
5
|
Ramirez-Olea H, Reyes-Ballesteros B, Chavez-Santoscoy RA. Potential application of the probiotic Bacillus licheniformis as an adjuvant in the treatment of diseases in humans and animals: A systematic review. Front Microbiol 2022; 13:993451. [PMID: 36225361 PMCID: PMC9549136 DOI: 10.3389/fmicb.2022.993451] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Accepted: 08/24/2022] [Indexed: 11/13/2022] Open
Abstract
The use of Bacillus licheniformis as a probiotic has increased significantly in recent years. Published reports demonstrate that it provides multiple benefits for health. Although there are already studies in humans and is marketed, it is mostly used in the veterinary industry still. However, its benefits could be extrapolated to humans in future. This review addresses the application of B. licheniformis, its sporulation, mechanisms of action, and its role in the resolution, treatment, and prevention of different conditions and diseases. It focuses on scientific advances from 2016 to mid-2022 and emphasizes the most common diseases in the general population. Most of the 70% of published studies about the health benefits of B. licheniformis have been published from 2016 until now. The intake of B. licheniformis has been related to the effects of modulation of the intestinal microbiota, antimicrobial activity, growth promotion, anti-inflammatory and immunostimulatory effects, promotion of the regulation of the lipid profile, increase of neurotransmitters, and stress reduction, among others. These results provide novel possible applications of this and other probiotics in general. Although many benefits can be reported on a microorganism, the combination with others could provide a better effect. Further studies like this need to be done to understand the specific advantages of each probiotic and its strains and therefore achieve a better selection of them for a specific disease or disorder.
Collapse
Affiliation(s)
- Hugo Ramirez-Olea
- Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Campus Monterrey, Monterrey, NL, Mexico
| | - Bernardo Reyes-Ballesteros
- Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Campus Estado de México, Ciudad López Mateos, MX, Mexico
| | - Rocio Alejandra Chavez-Santoscoy
- Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Campus Monterrey, Monterrey, NL, Mexico
- *Correspondence: Rocio Alejandra Chavez-Santoscoy,
| |
Collapse
|